Document is current

Article History

Accepted: 13 June 2021

First Online: 17 July 2021

Declarations

:

: This work was funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, and C18281/A15064, C18281/A24432). SS is funded by a National Institute for Health Research (NIHR) fellowship (PDF-2017-10-008). HT and RMM were supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funding source was not involved in the design of the study, the collection, analysis and interpretation of data or the writing of the manuscript.

: RMM and ET report grants from Cancer Research UK, during the conduct of the study. HT has received personal consulting fees from Novartis Pharma AG, Pfizer Inc, Roche Holding AG and Janssen Pharmaceutica. The funding received by HT was not related to the present publication or in a similar clinical area. EK has received personal consulting fees from Novartis Pharma AG, Pfizer Inc, and Roche Holding AG. The funding received by EK was not related to the present publication or in a similar clinical area.

: All authors were involved in drafting and approving the manuscript.

: Not applicable.